Genentech will voluntary withdraw the psoriasis drug Raptiva (efalizumab) from the U.S. market due to the association with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal CNS disease. Raptiva is indicated for the treatment of chronic moderate-to-severe plaque psoriasis in adults 18 years or older. There have been three cases of diagnosed PML in patients taking Raptiva and one patient who developed progressive neurologic symptoms but died of unknown...